Loading clinical trials...

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema | Clinical Trials | Clareo Health

COMPLETED

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks

NCT01541423•Shire

View on ClinicalTrials.gov

Summary

This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All patients must:
•Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of angioedema attacks
•Provide written informed consent/assent in compliance with applicable country-specific and local regulations

Exclusion Criteria

•All patients must not:
•Be receiving CINRYZE in an investigational study
•Be receiving another HAE therapy as part of a clinical trial

Locations (20)

Universitair Ziekenhuis Antwerpen (UZA)

Antwerp, Edegem, Belgium

Clinic St-Luc University Hospital

Brussels, Belgium

CHU d'Angers

Angers, France

Hôpital Claude-Huriez

Lille, France

Immunologie Clinique et Allergologie

Nancy, France

Hôpital Saint Antoine

Paris, France

Université Paris Descartes

Paris, France

Allergie-Centrum-Charite

Berlin, Germany

Universitätsklinik Essen

Essen, Germany

Johann Wolfgang Goethe Universität

Frankfurt, Germany

Key Dates

Start Date

May 11, 2012

Primary Completion Date

September 25, 2016

Completion Date

September 25, 2016

Last Updated

March 17, 2021

Enrollment

ACTUAL participants

Conditions

Hereditary Angioedema (HAE)

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447

Hereditary Angioedema (HAE)

View study

RECRUITINGPHASE3

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823

Hereditary Angioedema (HAE)

View study

ACTIVE_NOT_RECRUITING

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

NCT05469789

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

Inclusion Criteria

Exclusion Criteria

Donidalorsen Treatment in Children With Hereditary Angioedema

A Study of Navenibart in Participants With Hereditary Angioedema

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People